ElsevierDrugInformation
Pemivibart Injection
Learn more about Elsevier’s Drug Patient Education today! Empower and engage your patients to use medication safely.
PEMIVIBART (pem iv i bart) reduces the risk of COVID-19. It does not treat COVID-19. It is still possible to get COVID-19 after receiving this medication, but the symptoms may be less severe or not last as long. It works by helping people with a weak immune system fight off a future infection. It is a monoclonal antibody. The FDA has allowed the emergency use of this medication.
This medication is infused into a vein. It is given by your care team in a hospital or clinic setting.
Talk to your care team about the use of this medication in children. While it may be given to children as young as 12 years, precautions do apply.
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
This medication is given in a hospital or clinic. It will not be stored at home.
They need to know if you have any of these conditions:
Interactions have not been studied.
Keep appointments for follow-up doses. It is important not to miss your dose. Call your care team if you are unable to keep an appointment.
Your condition will be monitored carefully while you are receiving this medication. Visit your care team for regular health checks.
Tell your care team if you have received a COVID-19 vaccine in the last 14 days. This medication should be given at least 14 days after your vaccine.
Cookies são usados neste site. Para recusar ou saber mais, visite nosso conheça nosso aviso de cookies.
Copyright © 2024 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.